Aim: The primary aim of this study was to standardize the correlated effective dosage of
the antidiabetic drug empagliflozin (EMPA) and the antipsychotic drug olanzapine (Ola).
Background: Atypical antipsychotics are associated with BWG and metabolic disturbances for which
many approaches have been used to minimize these issues, including antidiabetic drugs. The antidiabetic
drugs have been quite effective in reversing BWG induced by the administration of antipsychotic
drugs in patients who have psychosis, schizophrenia and bipolar disorder.
Objective: The objective of this study was to standardize the correlated effective dosage of EMPA and
Methods: The study was carried out for 28 days to represent the chronic effect of Ola on female
Wistar rats. Rats were divided into three groups based on the dose they received: control (vehicle),
Ola-4 and Ola-8 (4 and 8 mg/kg/OD, respectively), and EMPA-10 and EMPA-20 (10 and 20
Results: Both doses of Ola produced a significant increase in the percentage of BWG, however, Ola-4
produced a higher BWG. Also, both the doses of EMPA were able to reverse the effect of Ola-induced
BWG; however, EMPA-20 produced a higher reversal in BWG and normalized the rat's body weight.
Conclusion: We conclude that Ola-4 and EMPA-20 were the most effective dosage for experimental
purposes in female Wistar rats. The findings of this study standardized the effective correlated dosage
of olanzapine and empagliflozin in female Wistar rats that will help understand the underlying molecular
and behavioral mechanisms.